ADMA Biologics Faces Legal Scrutiny Over Alleged Revenue Inflation Tactics
New York, Thursday, 7 May 2026.
Following a 29% stock crash, ADMA Biologics is under investigation for allegedly inflating its 2025 revenue growth to hide deteriorating demand for its medical products.
The Catalyst for Legal Scrutiny
On May 6, 2026, law firms Block & Leviton and Bleichmar Fonti & Auld LLP (BFA) announced investigations into ADMA Biologics, Inc. (Nasdaq: ADMA) for potential violations of federal securities laws [1][2]. The legal actions stem from allegations that the biopharmaceutical company engaged in a “channel stuffing” scheme to artificially inflate its 2025 revenue figures [2][3]. The controversy centers on ASCENIV, ADMA’s flagship liquid immune globulin solution used to treat Primary Humoral Immunodeficiency in adults and adolescents [2][3].
Financial Results and Withdrawn Guidance
The legal challenges coincide with a period of significant volatility for ADMA Biologics’ stock, which fell an additional 24 percent in after-hours trading on May 6, 2026 [1]. This latest sell-off was triggered by the company’s decision to withdraw its long-term financial guidance during its first-quarter 2026 earnings call, citing uncertainties in the competitive landscape [1][4]. The broader market for standard immunoglobulin products has seen an influx of new entrants since the latter half of 2025, leading to heavy discounting and an estimated 15 to 20 percent erosion in average selling prices for products like ADMA’s BIVIGAM [4].
Operational Metrics and Future Outlook
A critical metric drawing attention in the wake of the channel stuffing allegations is ADMA’s Days Sales Outstanding (DSO), a standard accounting measure of how quickly a company collects payment after a sale [GPT]. In the first quarter of 2026, ADMA’s DSO increased to approximately 107 days [4]. The company’s management has stated plans to improve this metric in the back half of 2026, targeting a DSO range of 90 to 105 days [4]. [alert! ‘Whether ADMA will successfully reduce its DSO to the targeted range remains uncertain given the ongoing competitive pressures and distributor dynamics.’]